Article Text

See original article:

Download PDFPDF

Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia
  1. C Olivieri1,
  2. E Mira2,
  3. G Delù2,
  4. F Pagella2,
  5. A Zambelli3,
  6. L Malvezzi2,
  7. E Buscarini3,
  8. C Danesino1
  1. 1Genetica Medica, Università di Pavia, Pavia, Italy
  2. 2Clinica Otorinolaringoiatrica, Università di Pavia, IRCCS S Matteo, Pavia, Italy
  3. 3Unità Operativa di Gastroenterologia, Ospedale Maggiore, Crema, Italy
  1. Correspondence to:
 Dr C Danesino, Genetica Medica, Via Forlanini 14, 27100 Pavia, Italy;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hereditary haemorrhagic telangiectasia (HHT) (OMIM 187300) is an autosomal dominant disorder caused by mutations in either of two genes, endoglin (ENG, OMIM 131195) (HHT1) and activin A receptor type II-like 1 (ACVRL1, OMIM 601284) (HHT2). Evidence for a third locus has also been reported.1

The product of the ACVRL1 gene is a type I receptor for the TGF-beta group of ligands; it is associated with the TGF-beta or activin type II receptors and the complex binds TGF-beta or activin. It is highly expressed in endothelial cells, lung, and placenta, as endoglin, mutations of which are observed in HHT1; endoglin is supposed to sequester TGF-beta and present the ligand to activin A receptor type II-like 1 plus a type II receptor.2 Mutations in ENG and ACVRL1 may cause HHT1 or HHT2, respectively, by disrupting this complex.

The clinical presentation, indistinguishable between HHT1 and HHT2, typically includes epistaxis and telangiectasia, and the diagnosis can be considered to be confirmed, according to the proposal of Shovlin et al,3 if three of the four suggested diagnostic criteria (epistaxis, telangiectasia, visceral lesions, positive family history) are present. The phenotype is highly variable and penetrance is complete by the age of 40 years.4

Arteriovenous (AV) fistulae are frequently observed in the liver (8% of patients),5 lungs (20%),6 and brain5 and may cause severe life threatening complications. Neurological complications (strokes, cerebral abscesses, seizures) may be prevented with appropriate treatment of the pulmonary arteriovenous malformations (PAVMs). A higher risk for lung involvement has been suggested in patients carrying mutations in the ENG gene,7 while in some families with a peculiar liver involvement, mutations in ACVRL1 have been described.8 The involvement of the latter gene has also been reported in a single patient with a pituitary tumour9 without any overt sign of HHT and in families with HHT and pulmonary hypertension.10

The number of mutations identified so far is limited; in particular for ACVRL1 only 29 mutations have been reported (table 1), always in single patients or in very small series. The mutations are scattered along the gene; there is not, at present, any mutation occurring with significantly higher frequency, and exons 3, 7, and 8 seem to harbour about 59% of the known mutations.2,8–15 Based on these data, we decided to test our group of patients for the presence of mutations in these three exons, to verify if analysis of part of the ACVRL1 gene may result in the attribution of a consistent number of unselected patients to HHT2.

Table 1

Summary of the mutations already published for the ACVRL1 gene

We describe here SSCP and/or dHPLC screening for exons 3, 7, and 8 in a group of 52 unselected HHT patients.


Patients affected by HHT were diagnosed by EB or EM using the published criteria.3 All patients are of Italian ancestry and details on the city of origin of each family were also obtained. Detailed clinical data will be reported elsewhere.

We collected blood samples, after informed consent, from 54 index cases and from available relatives at risk of being affected on the basis of the family pedigree; two of them belonged to large families in which linkage analysis showed the involvement of ENG and were excluded from ACVRL1 analysis.

DNA from the remaining 52 index cases was extracted by routine techniques; exons 3, 7, and 8 were amplified with the primers reported by Berg et al11 and analysed by SSCP with two different running conditions16 in order to reduce false negative results (exon 3, which contains a common polymorphism) or dHPLC plus SSCP (exons 7 and 8).

In each experiment, a control for which the presence of a wild type sequence had previously been shown by direct sequencing and, for exon 3, a carrier of the common polymorphism were also included.

All subjects displaying an SSCP (or dHPLC) pattern different from controls or carriers of the common polymorphism of exon 3 were sequenced, using the Big Dye terminator method associated with Taq FS enzyme (Cycle Sequencing reaction) and an ABI-PRISM 3700 DNA analyser (Applied Biosystems).

The sequences obtained were compared to the reported gene sequence (working draft NT 009609) using the BLASTN program.


The 13 different mutations in exons 3, 7, and 8 found in 16 unrelated probands after screening the 52 HHT patients are reported in table 2.

Table 2

Summary of the mutations found

Only the mutation found in case LPV has been already reported,11 while the others are all new. Four mutations (cases LL, PS, SA, VC, table 2) cause a frameshift and introduce a stop codon and two mutations (cases Dit201 and MoA, table 2) introduce a stop codon; thus these six mutations are certainly responsible for the production of a truncated and defective protein.

Two mutations occurred twice (delH97N98 and R67W), but no relationship could be found up to the great grandparents for each couple of families; however, in both cases the family names originate from closely related geographical areas in north Italy.

Del H97N98 deletes two amino acids of the extracellular domain, where N98 is a potential glycosylation site; the two amino acids are conserved in Mus musculus and Rattus norvegicus and N98 is also conserved in Xenopus laevis and Gallus gallus. R67 is conserved in mouse and rat while a homologous amino acid is present in Xenopus laevis and Gallus gallus. The presence of the same change at a conserved amino acid in two unrelated (or distantly related) families is a point in favour of its causal relation to the disease. The same changes were not observed in any other allele examined (n=50).

P301, carrying the R67W mutation (table 2) was found in a family previously reported as unlinked to either chromosome 9 or 12.17 After re-evaluation of all family members according to the updated diagnostic criteria3 and a new linkage analysis, the evidence for exclusion of chromosome 9 remained strong, while the evidence for the exclusion of chromosome 12 was not significant; thus, the proband was included in the study. The extensive liver involvement in this family is confirmed and it is noteworthy that intrahepatic AV shunts are also present in the apparently unrelated family sharing the same mutation (case MC, table 2), which comes from the same geographical region. A different missense mutation at the same position, R67Q, was reported by Berg et al,7 confirming that the substitution of this arginine causes HHT2. In addition, Lux et al18 have shown the loss of signalling activity in vitro for mutations C51Y (case 3 in table 2) and R67Q.

The amino acid changes D330Y, C344F, A352P, P378L, and A400D (table 2, fig 1) all occur at highly conserved residues (Rattus norvegicus, Xenopus laevis, Gallus gallus, Drosophila melanogaster), so they are very likely to produce protein changes causing the disease. None of them has been found in any other examined allele (n=50).

Figure 1

Alignment of amino acid sequences for genes orthologous to ACVRL1. (1) Homo sapiens. (2) Rattus norvegicus. (3) Xenopus laevis. (4) Gallus gallus. (5) Drosophila melanogaster. Amino acids identical to the human sequence are in bold. Conserved substitutions are underlined. * indicates the position of the missense mutations of cases 11, 12, 13, 15, and 16.

The cosegregation of the mutations with the disease was analysed and shown in families of cases LPV, Dit201, MC, P301, VG, and Iac302, for which other affected members were available.

The genotypes of the common polymorphism of exon 3 c(intron 3 5`IVS+11)t (cp3), reported in the HHT mutation database, but not formally published, were found equally distributed in the whole group of HHT patients and in the control population (CC/CT/TT: 33.9/49.0/17.1 in patients and 30.8/ 53.8 /15.4 in controls); the overall C allele frequency is 0.58 and Hardy Weinberg equilibrium is conserved. In the families of cases Dit201, P301, and MC, cp3 did not segregate with the disease.

We also analysed the short tandem repeat (STR) D12S1677 which is located between exons 9 and 10; the size of the alleles was randomly distributed among the 52 probands and the probands of the two families carrying the same mutations shared one (cases PP/VG in table 2) or both D12S1677 alleles (cases MC/P301 in table 2).

The 29 mutations in the ACVRL1 gene reported so far in patients affected by HHT2 (table 1) are distributed in eight of the nine coding exons, but exons 3, 7, and 8 contain 59% of them. No mutations have been reported more than twice and no data on geographical distribution are available. Owing to the small number of mutations identified and to the extremely wide phenotypic variability, no detailed phenotype-genotype correlation is known.

A much lower incidence of lung AV malformation in ACVRL1 linked families was suggested by Berg et al,7 but recently Kjeldsen et al14 reported a T1193A (exon 8) mutation in a family with a high prevalence of PAVM and Trembath et al10 identified ACVRL1 mutations in HHT patients with clinical manifestations typical of primary pulmonary hypertension.

McDonald et al8 reported in a single large family that the mutation G998T (exon 7) was associated with a significantly higher liver involvement, with 17% of screened patients showing liver AV fistulas. They proposed that these clinical findings may be specific for the mutation, and stressed the extreme variability present even in subjects carrying the same mutation.

Intrahepatic AV shunts were present in six of the 10 patients carrying mutations in the ACVRL1 gene who agreed to undergo liver ultrasound examination. A positive family history for similar liver involvement is present in the families of cases P301, MC, and FP. In the same set of patients, lung x rays and pulse oximetry consistently yielded normal results. Our findings suggest the hypothesis that mutations in the ACVRL1 gene may be associated with higher risk of liver AV malformations.

Key points

  • Our work aimed to identify new mutations in the ACVRL1 gene, and to collect data on liver involvement in HHT patients carrying mutations in this gene.

  • We studied exons 3, 7, and 8 of ACVRL1 by SSCP and/or dHPLC in a group of 52 unselected HHT patients diagnosed according to recently published criteria. All patients are of Italian background. Samples showing abnormal patterns with either method were sequenced.

  • We observed 13 new unpublished mutations (two of them occurring twice); a previously reported mutation was also observed. The 16 mutations were distributed as follows: eight mutations in exon 3 and four mutations in both exons 7 and 8. Among the 16 patients thus identified as HHT2, 10 agreed to undergo liver ultrasound examination and six were found to be carriers of intrahepatic arteriovenous shunts.

  • A review of published reports showed that 17/29 reported mutations were localised in exons 3, 7, and 8 of the ACVRL1 gene in HHT2 patients; our results confirm that these exons carry a large number of mutations and that the mutations related to HHT2 are mostly different from each other. The presence of intrahepatic arteriovenous shunts was also found in a significant number of patients carrying the mutations.

Exon 3 contains information for the extracellular domain, while exons 7 and 8 contain information for a portion of the intracellular tyrosine kinase domain; however, at present, it is not possible to correlate precisely changes in the different segments of the protein with specific clinical symptoms.

Testing by SSCP and/or dHPLC exons 3, 7, and 8 of ACVRL1 and sequencing only cases showing abnormal patterns allowed us to show that 30.7% of a group of 52 unselected HHT Italian patients may be classified as HHT2.

The prevalence of the disorder in the population is not well determined, probably because of the wide phenotypic variability; the best available estimates are those for a well defined region of Haut-Jura, Lyon, France5 and for the county of Fyn, Denmark,14 in which a prevalence of 15.6 per 100 000 was calculated. In our sample, the geographical origin of the families was evenly distributed over the whole of Italy so there is no evidence for a specific geographical aggregation of the disease in Italy as in France5; preliminary unpublished data by EB indicate a prevalence of 18/100 000 in the region of Piacenza, in northern Italy.

The probands from two pairs of families (MC and P301, and PP and VG, respectively, table 2) shared the same mutations, one or two alleles at the intronic D12S167 polymorphism and at the common polymorphism, and came from the same geographical area. Thus, they are very like to have a common ancestor.

In conclusion, we report a consistent number of new mutations in the ACVRL1 gene identified in a large series of unselected Italian HHT patients; for six mutations an association with intrahepatic AV shunts was also documented. Our results contribute to the understanding of the spectrum of ACVRL1 mutations leading to HHT2 and the high rate of intrahepatic AV shunts in HHT2, if confirmed, will have relevant implications for genetic counselling and clinical management of patients.


The last two authors contributed equally to this work. We wish to thank the patients and their families for their cooperation and the association “Fondazione Italiana HHT-Onlus Onilde Carini” for their support. We thank Mr A Pilotto for his skilful collaboration in performing dHPLC. This work was partially supported by “IRCCS Policlinico S Matteo-Pavia, Italy, grant “ricerca corrente” to EM.

Data access: HGMD, Human Gene Mutation database, (; BLAST, (; NCBI codes for protein alignment (fig 1): ( Homo sapiens: 4557243 (NP_000011), Rattus norvegicus: 11967973 (NP_071886), Xenopus laevis: 2439947, (AAB71328), Gallus gallus: 14270376 (CAC39433); Drosophila melanogaster: 642862 (AAA61946).


Linked Articles

  • Correction
    BMJ Publishing Group Ltd